The oral capsule format is designed for gastrointestinal pharmacology studies investigating local GI effects (gastric ulcer models, IBD models) and systemic bioavailability via the oral route
Rather, in my view, it is the tell: People who start these drugs were already at lower cancer risk, and the GLP-1 drugs are getting credit for that preexisting advantage
Its just a coincidence that they found an effect in diabetes first. Kariya and other companies are now pursuing the use of these drugs to treat neurodegeneration
Start your intake Why Semaglutide Doesn't Eliminate Hunger in Every Person Semaglutide mimics glucagon-like peptide-1, a hormone that signals fullness to your brain's hypothalamus
Stay consistent, give your body time to adapt and let your long-term dedication bring sustainable transformation
Based on the multidisciplinary expert consensus on managing GLP-1 GI side effects: While dehydration can affect anyone on GLP-1 medications, certain groups face higher risk: GI tolerability of semaglutide 2.4 mg (STEP 1-3 pooled analysis) 74% GI adverse events in semaglutide group vs 48% placebo